DxUpClose, a Dallas, Texas-based developer of an in-vitro antibiotic sensitivity test for use at point-of-care, designed to deliver results in less than an hour, has raised $1m in Series A funding from Golden Seeds.
The company intends to use the capital to complete the development of the product, enhance sensitivity of the diagnostic, and achieve FDA’s design verification milestone.
founded in 2009 by Cyndi Nickel, CEO, DxUpClose is advancing an electronic sensor that does three things within one hour at the patient’s bedside:
– list antibiotics proven to be effective against the bacteria,
– screen for deadly bacteria, and
– count bacteria present.
In conjunction with the financing, Jan Norton, Managing Director, Golden Seeds, co-led the financing and joined the company’s board as an observer.